|Title:||Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia||Authors:||Ooi C.J.
De Silva J.H.
on behalf of the Asia-Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease
Asian Organization for Crohn's
|Keywords:||adalimumab; biosimilar; Crohn's disease; inflammatory bowel disease; infliximab; ulcerative colitis||Issue Date:||2019||Publisher:||Blackwell Publishing||Journal Volume:||34||Journal Issue:||8||Start page/Pages:||1296-1315||Source:||Journal of Gastroenterology and Hepatology (Australia)||Abstract:||
The Asia–Pacific Working Group on Inflammatory Bowel Disease was established in Cebu, Philippines, under the auspices of the Asia–Pacific Association of Gastroenterology with the goal of improving inflammatory bowel disease care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in conjunction with conventional treatments for ulcerative colitis and Crohn's disease in Asia. These statements also address how pharmacogenetics influences the treatments of ulcerative colitis and Crohn's disease and provides guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of inflammatory bowel disease workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing, and future revisions are likely as new data continue to emerge. ? 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
|ISSN:||0815-9319||DOI:||10.1111/jgh.14648||SDG/Keyword:||adalimumab; antivirus agent; azathioprine; biological product; biosimilar agent; C reactive protein; calgranulin; corticosteroid; cyclosporine; hepatitis B core antibody; hepatitis B surface antibody; hepatitis B surface antigen; immunomodulating agent; mercaptopurine; tumor necrosis factor inhibitor; biological product; immunologic factor; Asia; capsule endoscopy; clinical practice; comorbidity; Crohn disease; disease activity; hepatitis B; human; irritable colon; pharmacogenetics; practice guideline; priority journal; Review; treatment response; tuberculosis; ulcerative colitis; benchmarking; clinical decision making; consensus; consensus development; Crohn disease; Delphi study; immunology; patient selection; risk factor; treatment outcome; ulcerative colitis; Asia; Benchmarking; Biological Products; Clinical Decision-Making; Colitis, Ulcerative; Consensus; Crohn Disease; Delphi Technique; Humans; Immunologic Factors; Patient Selection; Pharmacogenetics; Risk Factors; Treatment Outcome
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.